心不全の治療の効果と安全性 脆弱性状態による: 体系的なレビュー
Charlotte M Nijskens1,2, Louis Handoko3,4,5, Sharon Remmelzwaal2,6,7
1Department of Internal Medicine, Geriatrics Section Amsterdam UMC Location Vrije Universiteit Amsterdam Amsterdam The Netherlands.
Journal of the American Heart Association
|August 29, 2025
まとめ
心不全 (HF) のガイドラインによる治療は,弱い患者にとって安全で有効です. 懸念にもかかわらず,これらの治療は弱い個体においてより大きな絶対的なリスク削減を提供し,その使用を支持しています.
科学分野:
- 心臓病科
- 高齢者医療
- 臨床試験
背景:
- 心不全 (HF) のガイドラインによる治療は,不耐性の懸念により,弱い患者ではしばしば拒否されます.
- 脆弱な患者はHFの合併症のリスクが高く,治療の潜在的利益を示唆しています.
- このレビューでは,異なる脆弱性レベルのHF治療の有効性と安全性を評価しています.
研究 の 目的:
- 心不全患者の治療の有効性と安全性を体系的に検討する.
- 脆弱性の状態がHF介入の結果にどのように影響するかを評価する.
主な方法:
- HF治療に関するランダム化臨床試験の体系的レビュー
- Medline,Embase,Web of Scienceで 脆弱性による結果を報告した研究を検索しました
- 収穫図と可能なメタ解析を用いてデータをまとめました.
主要な成果:
- 12件の研究が含まれており,6件は医薬品,3件は運動/リハビリテーション,その他は疾患管理,テレモニタリング,インプラント可能な心臓動脈除細動器に関する研究でした.
- ほとんどの介入は弱さとの有意な相互作用を示さなかったが,一部の介入は特定のアウトカムのために弱体患者を好んだ.
- 埋め込み式心動除細動器では有意な相互作用は認められませんでした.
結論:
- 心不全の治療は,移植性心動除細動器を除いて,弱体患者および弱体でない患者の両方に安全です.
- 効果は似ているが,発症率が高いため,絶対リスクの低下は弱体患者より大きい.
- 心不全の患者では,ガイドラインによる治療を考慮する必要があります.
さらに関連する動画
05:53Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
16.7K
07:27Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
Published on: October 6, 2016
10.4K
関連する概念動画
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:30Heart Failure VII: Nursing Interventions
139
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
139
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505